

---

# Interferon Alpha-2b in the Treatment of Chronic Hepatitis C: Early Experience

Nathaniel P.H. Ching MD \*, James Lumeng MD \*\*, Ronald Pang MD \*\*, Glenn Pang MD\*\*,  
Fung Wa Or MPH\*\*\*, Natascha W.H. Ching MD, and Clara Ching PhD \*\*\*

*The antiviral and immunomodulatory effects of interferon were assessed in the treatment of chronic Hepatitis C in multi-ethnic patients to prevent viral replication and chronic liver damage. Three million units of recombinant interferon alpha-2b were administered three times a week for 48 weeks to a group of 9 active Hepatitis C patients. A clinical response was defined as normalization of serum ALT values. Serum was frozen and stored for Hepatitis C viral assays. Four patients normalized their liver functions. When viral levels were measured only two patients had unmeasurable levels of HCV RNA after treatment. Therapeutic results were observed and much work needs to be done to improve therapy because a serious epidemic is predicted for the future.*

## Introduction

The Federal Drug Administration approved Interferon alpha-2b for the treatment of chronic Hepatitis C in February 1991. The Hepatitis C antigen was identified in 1989 and an antibody test developed soon thereafter; prior to this, Hepatitis C was referred to as Non-A Non-B Hepatitis. Interferon has been shown currently to be the most effective therapy in approximately 30 to 40% of chronic Hepatitis C patients<sup>1-3</sup> because of its antiviral and immunomodulatory effects. The reports leading to FDA approval looked promising so interferon therapy was utilized for our patients soon after FDA approval and forms the basis for this report of our early experiences. Our group was referred the Hepatitis C Virus (HCV) cases for treatment because of our experience in a research project to treat chronic Hepatitis B patients.<sup>4</sup>

\*Departments of Surgery and \*\*\*Medicine  
John A Burns School of Medicine  
at St. Francis Medical Center  
University of Hawaii and  
Department of Medicine  
\*\*St. Francis Medical Center  
Honolulu, Hawaii

Supported in part by a grant from the  
Hawaii Department of Health,  
Hawaii Medical Association and  
Cancer Federation, Inc.

Address correspondence and  
requests for reprints to:  
Nathaniel Ching, M.D.  
1360 S Beretania St, Suite 400  
Honolulu, Hawaii 96814

Chronic Hepatitis B is a major public health problem in Hawaii because of the large immigrant population from Asia and the Pacific Basin. Exposure to Hepatitis B virus (HBV) often results in chronic Hepatitis that can significantly increase the risk of developing cirrhosis and hepatocellular carcinoma. Hepatitis C can develop into these same fatal complications. The recent NIH Consensus Conference on Hepatitis C notes that 4 million people in the United States are currently infected with HCV with about 30,000 new cases a year with the numbers to double or triple in the next 20 to 30 years.<sup>5</sup> It will be a major public health problem until an effective therapy and vaccine can be developed.

## Materials and Methods

### Patient Population

Patients testing positive for the first generation HCV antibody test (Ortho Diagnostics, New Jersey) and negative for Hepatitis B antigens or antibodies were referred for evaluation for treatment. Patients with elevated liver function tests, primarily ALT  $\geq 1.5X$  high normal level for over 6 months, were then selected for treatment according to the FDA approved protocol. Patients were excluded if they showed evidence of cirrhosis as reflected in their alkaline phosphatase levels. Informed consent was obtained.

### Interferon Therapy

Chronic active Hepatitis C patients were treated with recombinant interferon alpha-2b (Intron-A, Schering-Plough Corporation, Kenilworth, NJ). Three million units were administered subcutaneously 3 times per week for 48 weeks. If there was no clinical response, another 48 week course was offered. Patients received their injections in the Ambulatory Oncology Clinic or chose to voluntarily self-administer their medication after training by the Oncology Nursing Staff. The dose was reduced to 1-2 million units when platelets were  $<100,000$  or granulocytes were  $<1000$ .

### Evaluation During Therapy

Patients were evaluated during therapy for hematological and biochemical profiles. Blood was collected for complete blood and platelet counts and liver function tests (LFTs) including serum alanine and aspartate aminotransferase and gamma glutamyl transpeptidase activities (ALT, AST, GGPT) prior to therapy, after 2 weeks, monthly during therapy and 2-3 months post therapy. Liver function tests were performed by Immunoassay (EIA) (Abbott Laboratories, Abbott Park, IL). All evaluations were performed by the same Clinical Laboratory. A clinical response was defined as normalization of ALT levels.

## Hepatitis C Virus (HCV) Assay

Aliquots of serial serum samples from each patient were drawn at baseline, 2-3 month intervals during therapy, the end of therapy and 2-3 months following therapy and stored at  $-70^{\circ}\text{C}$  for analysis when more specific viral tests were available. The first generation test for HCV antibody was performed in the clinical laboratory. Sera drawn during therapy were frozen for later batch analysis for HCV-RNA by reverse transcription-polymerase reaction (RT-PCR) by Lawrence Lumeng MD, Department of Gastroenterology, Indiana University School of Medicine. RT-PCR analysis for the 256BP and 157BP regions confirmed the diagnosis of HCV but it was only semi-quantitative.

Branched HCV RNA analysis was performed by Reference Laboratory Alliance (Pittsburgh, PA).<sup>6</sup> HCV-RNA is quantifiable at levels  $>3.5 \times 10^5$  Eq/ml but is not FDA cleared for diagnostic use and may not constitute the sole basis for patient diagnosis. HCV-RNA in a patient's sample is captured and hybridized to several target probes corresponding to the conserved 5' nontranslated region of HCV. Amplification of signal from the hybridizations is achieved by addition of branched DNA molecules which can bind multiple copies of enzyme emitted and measured by a luminometer. Concentrations of viral target in individual specimens were determined by comparison with a standard curve.

HCV genotype determination was performed on the baseline samples by RT-PCR at Reference Laboratory Alliance (Pittsburgh, PA). The INNO-LIPA (line probe assay) is a reverse hybridization for the differentiation of the various HCV genotypes. DNA representing a sequence from the 5' nontranslated region was amplified using biotinylated primers. Amplified DNA was hybridized to specific oligonucleotide-probes immobilized on membrane strips. Hybridizations were visualized by reaction of alkaline phosphatase, bound to amplified DNA, with chromogenic substrate. The pattern of reactivity of a simplified fragment with one or more lines upon the test strip allows recognition of five major HCV genotypes (Genotype 1-5) and 6 subtypes (1a, 1b, 2a, 2b, 3a, 3b).

## Statistical Analysis

Results are expressed as arithmetic mean  $\pm$  SD except where noted. Data was analyzed with the Sigma Stat program (Jandel Scientific, San Rafael, CA). Continuous variables were analyzed by linear regression or Analysis of Variation (ANOVA) techniques. The IBM 55SX -PS2 computer was used for the analysis.

## Results

### Study Population


Eleven patients were referred for evaluation for treatment; one patient did not qualify because of associated Hepatitis B involvement and evidence of cirrhosis. One of the remaining ten patients was a young patient from a drug rehabilitation program who ran away from his program and did not return for further treatment after his first injection. The remaining nine patients treated ranged in ages of 35-69 years; 6 of the 9 were males. Baseline liver function tests (ALT, AST and GGPT) were increased in the patients: ALT =  $195 \pm 121$  IU/L, AST =  $111 \pm 64$  IU/L, GGPT =  $115 \pm 109$  IU/L. The risk factors identified for Hepatitis C were blood or blood products transfusion (3) and confessed unspecified drug usage (2); no history of any other recognized risk factor was obtained from the remaining

4 patients. There was only one foreign born patient (Korea); the remaining patients were from Hawaii, Guam or the mainland US.

## Toxicity

Patients initially experienced flu-like symptoms, including myalgia, headache and fever which generally improved after the first week or two of therapy; one patient (#905) had severe constitutional symptoms which responded to dose reduction. The nine patients tolerated their regimens and completed therapy. One patient (#934) required dose reductions due to decrease in wbc's and platelets.

Fig 1.— Changes in ALT levels of chronic active Hepatitis C patients on interferon therapy,  $X \pm$ SD. Elevated levels at baseline decreased but not to normal levels in all patients.



## Biochemical Liver Function Tests

ALT levels decreased in all patients during treatment,  $P < .05$  (Fig 1), but only 4 patients normalized their ALT levels. One patient, #905, who was infected after blood transfusion had normalized her liver function tests after the first 6 months of treatment; she flared to exceptionally high levels of ALT and was started on another course of treatment. She responded to another 6 months of therapy with continued normal liver function tests thereafter. The patients who did not normalize had continued elevated levels or increased after cessation of therapy.

## Hepatitis C Virus (HCV) Assay

All patients were confirmed for the presence of HCV by PCR analysis. Serial analysis during treatment of the patients only demonstrated the disappearance of both BP256 and BP157 markers in one patient, again #905, demonstrating eradication of the virus. This patient had flared her LFTs and required a second course of treatment.

Baseline levels of branched HCV RNA analysis ranged from 8.4-862.7  $10^5$  Eq/ml. The 4 patients who normalized their LFTs had baseline levels of 8.4, 26.6, 66.9 and 108.2  $10^5$  Eq/ml. Only two of the four patients developed unmeasurable levels of HCV RNA after therapy whose baseline levels were 8.4 and 26.6 respectively. The lower baseline levels of HCV RNA may possibly predict a better response.

HCV genotype analysis demonstrated a preponderance of genotype 1, 7/9 patients. There was only single incidences of type 2 and

# AZELEX<sup>®</sup>

(AZELAIC ACID CREAM) 20%

For Dermatologic Use Only Not for Ophthalmic Use

**DESCRIPTION:** AZELEX<sup>®</sup> (azelaic acid cream) 20% contains azelaic acid, a naturally occurring saturated dicarboxylic acid. Structural Formula: HOOC-(CH<sub>2</sub>)<sub>7</sub>-COOH. Chemical Name: 1,7-heptanedicarboxylic acid. Empirical Formula: C<sub>9</sub>H<sub>16</sub>O<sub>4</sub>. Molecular Weight: 188.22. **Active Ingredient:** Each gram of AZELEX<sup>®</sup> contains azelaic acid 0.2 gm (20% w/w). **Inactive Ingredients:** cetylal octanoate, glycerin, glyceryl stearate and cetylal alcohol and cetyl palmitate and cocoglycerides, PEG-5 glyceryl stearate, propylene glycol and purified water. Benzoic acid is present as a preservative. **CLINICAL PHARMACOLOGY:** The exact mechanism of action of azelaic acid is not known. The following *in vitro* data are available, but their clinical significance is unknown. Azelaic acid has been shown to possess antimicrobial activity against *Propionibacterium acnes* and *Staphylococcus epidermidis*. The antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis. A normalization of keratinization leading to an anticomedonal effect of azelaic acid may also contribute to its clinical activity. Electron microscopic and immunohistochemical evaluation of skin biopsies from human subjects treated with AZELEX<sup>®</sup> demonstrated a reduction in the thickness of the stratum corneum, a reduction in number and size of keratohyalin granules, and a reduction in the amount and distribution of filaggrin (a protein component of keratohyalin) in epidermal layers. This is suggestive of the ability to decrease microcomedo formation. **Pharmacokinetics:** Following a single application of AZELEX<sup>®</sup> to human skin *in vitro*, azelaic acid penetrates into the stratum corneum (approximately 3 to 5% of the applied dose) and other viable skin layers (up to 10% of the dose is found in the epidermis and dermis). Negligible cutaneous metabolism occurs after topical application. Approximately 4% of the topically applied azelaic acid is systemically absorbed. Azelaic acid is mainly excreted unchanged in the urine but undergoes some  $\beta$ -oxidation to shorter chain dicarboxylic acids. The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics. Azelaic acid is a dietary constituent (whole grain cereals and animal products), and can be formed endogenously from longer-chain dicarboxylic acids, metabolism of oleic acid, and  $\omega$ -oxidation of monocarboxylic acids. Endogenous plasma concentration (20 to 80 ng/mL) and daily urinary excretion (4 to 28 mg) of azelaic acid are highly dependent on dietary intake. After topical treatment with AZELEX<sup>®</sup> in humans, plasma concentration and urinary excretion of azelaic acid are not significantly different from baseline levels. **INDICATIONS AND USAGE:** AZELEX<sup>®</sup> is indicated for the topical treatment of mild-to-moderate inflammatory acne vulgaris. **CONTRAINDICATIONS:** AZELEX<sup>®</sup> is contraindicated in individuals who have shown hypersensitivity to any of its components. **WARNINGS:** AZELEX<sup>®</sup> is for dermatologic use only and not for ophthalmic use. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexions, these patients should be monitored for early signs of hypopigmentation. **PRECAUTIONS: General:** If sensitivity or severe irritation develop with the use of AZELEX<sup>®</sup>, treatment should be discontinued and appropriate therapy instituted. **Information for patients:** Patients should be told: 1. To use AZELEX<sup>®</sup> for the full prescribed treatment period. 2. To avoid the use of occlusive dressings or wrappings. 3. To keep AZELEX<sup>®</sup> away from the mouth, eyes and other mucous membranes. If it does come in contact with the eyes, they should wash their eyes with large amounts of water and consult a physician if eye irritation persists. 4. If they have dark complexions, to report abnormal changes in skin color to their physician. 5. Due in part to the low pH of azelaic acid, temporary skin irritation (pruritus, burning, or stinging) may occur when AZELEX<sup>®</sup> is applied to broken or inflamed skin, usually at the start of treatment. However, this irritation commonly subsides if treatment is continued. If it continues, AZELEX<sup>®</sup> should be applied only once-a-day, or the treatment should be stopped until these effects have subsided. If troublesome irritation persists, use should be discontinued, and patients should consult their physician. (See ADVERSE REACTIONS.) **Carcinogenesis, mutagenesis, impairment of fertility:** Azelaic acid is a human dietary component of a simple molecular structure that does not suggest carcinogenic potential, and it does not belong to a class of drugs for which there is a concern about carcinogenicity. Therefore, animal studies to evaluate carcinogenic potential with AZELEX<sup>®</sup> Cream were not deemed necessary. In a battery of tests (Ames assay, HGPRT test in Chinese hamster ovary cells, human lymphocyte test, dominant lethal assay in mice), azelaic acid was found to be nonmutagenic. Animal studies have shown no adverse effects on fertility. **Pregnancy: Teratogenic Effects: Pregnancy Category B.** Embryotoxic effects were observed in Segment I and Segment II oral studies with rats receiving 2500 mg/kg/day of azelaic acid. Similar effects were observed in Segment II studies in rabbits given 150 to 500 mg/kg/day and in monkeys given 500 mg/kg/day. The doses at which these effects were noted were all within toxic dose ranges for the dams. No teratogenic effects were observed. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. **Nursing Mothers:** Equilibrium dialysis was used to assess human milk partitioning *in vitro*. At an azelaic acid concentration of 25  $\mu$ g/mL, the milk/plasma distribution coefficient was 0.7 and the milk/buffer distribution was 1.0, indicating that passage of drug into maternal milk may occur. Since less than 4% of a topically applied dose is systemically absorbed, the uptake of azelaic acid into maternal milk is not expected to cause a significant change from baseline azelaic acid levels in the milk. However, caution should be exercised when AZELEX<sup>®</sup> is administered to a nursing mother. **Pediatric Use:** Safety and effectiveness in pediatric patients under 12 years of age have not been established. **ADVERSE REACTIONS:** During U.S. clinical trials with AZELEX<sup>®</sup>, adverse reactions were generally mild and transient in nature. The most common adverse reactions occurring in approximately 1-5% of patients were pruritus, burning, stinging and tingling. Other adverse reactions such as erythema, dryness, rash, peeling, irritation, dermatitis, and contact dermatitis were reported in less than 1% of subjects. There is the potential for experiencing allergic reactions with use of AZELEX<sup>®</sup>. In patients using azelaic acid formulations, the following additional adverse experiences have been reported rarely: worsening of asthma, vitiligo depigmentation, small depigmented spots, hypertrichosis, reddening (signs of keratosis pilaris), and exacerbation of recurrent herpes labialis. **DOSAGE AND ADMINISTRATION:** After the skin is thoroughly washed and patted dry, a thin film of AZELEX<sup>®</sup> should be gently but thoroughly massaged into the affected areas twice daily, in the morning and evening. The hands should be washed following application. The duration of use of AZELEX<sup>®</sup> can vary from person to person and depends on the severity of the acne. Improvement of the condition occurs in the majority of patients with inflammatory lesions within four weeks. **HOW SUPPLIED:** AZELEX<sup>®</sup> is supplied in collapsible tubes in a 30 g size - NDC 0023-8694-30. **Note:** Protect from freezing. Store between 15°-30°C (59°-86°F). **Caution:** Federal (U.S.A.) law prohibits dispensing without a prescription. Distributed under license: U.S. Patent No. 4,386,104.

**ALLERGAN**  
SKINCARE


©1997 Allergan, Inc., Irvine, CA 92612, U.S.A.

type 3 genotype groups. Three of the four patients with a clinical response were type 1 or 1b and the fourth was type 3a; the complete responder was type 1b. The relationship of branched chain HCV RNA levels and genotype classification and clinical response is summarized in Table 1.

## Discussion

We were able to achieve a clinical response in four out of nine patients completing therapy in this early utilization of Interferon alpha-2b therapy for Hepatitis C infection which is consistent with the results of other trials. However, the antiviral effect of interferon did not correspond to the clinical response; only two patients achieved unmeasurable levels of HCV RNA and only one of these two had no trace of HCV with the sensitive PCR analysis. Grecht et al<sup>6</sup> report that high viremia titers were associated with advanced stages of the disease. Low baseline HCV RNA levels are reported by other investigators<sup>7,8</sup> to be predictors of successful therapy, which may also be seen in some of our responders to interferon treatment.

In the United States, genotype 1 accounts for about 75% of chronic HCV infections with half belonging to the 1a subtype and half to the 1b subtype. Genotype 2 accounts for 10-20% of isolates in the US and genotype 3 for another 5% of isolates. The distribution of HCV genotype in our study group follows these reports. Genotypes 4, 5 and 6 are rarely seen in the USA and when identified usually represents infection acquired abroad. Studies have documented higher rates of long-term response to alpha interferon in patients infected with genotypes 2a, 2b, or 3a compared with genotype 1.<sup>8-11</sup> Chemello and Alberti<sup>12</sup> reports only 29% long term response for type 1, versus 52% for type 2 and 74% for type 3 patients. The predominance of type 1 virus in Hawaii demonstrates a lowered chance of successful therapy in our patients. In contrast type 2 predominates in the Japanese patients (69%) with 18 (%) Type 3; this gives them a greater probability of successful therapy than our population.<sup>13</sup> One type 3 patient had a clinical response and developed unmeasurable levels of HCV RNA. The one complete responder to all three viral measurements was genotype 1b; three of four clinical responders were serotype 1b or 1. In this study the genotype of HCV did not aid in identifying probable responders except for one type 3 patient who had a low level of HCV RNA (8.4) at baseline.



## mel r. hertz MBA, CFP

Certified Financial Planner

Retirement Plans  
•  
Investment Management Consulting  
•  
Charitable Remainder Trusts

**522-0100**

Pacific Tower, Suite 2944, 1001 Bishop Street  
**derand**

capital management group

Services offered through H.C. Network Securities, Inc.  
H.C. is member NASD and SIPC. Terms of offering  
services through Associated Financial Planners, Inc. (AFPI)



Registered Investment Advisor: mel r. hertz is a registered  
advisor of H.C. and an associated person of H.C. under  
AFPI both of which are otherwise unaffiliated with Hertz

**Table 1.—Viral Genotype, HCV-RNA and Clinical Response**

Patient No.	Sex	Genotype	Clinical Response	HCV RNA ** Baseline	HCV RNA End
904	F	1	+	108.2	104.3
905*	F	1b	+	26.6	<3.4
910	M	1a	-	862.7	109.4
913	M	1	-	113.1	140.4
934*	M	1b	-	45.6	44.9
961	F	3a	+	8.4	<3.4
962	M	1a	-	186.9	19.4
963	M	1b	+	66.9	42.3
964	M	2b	-	113.1	34

\*—Dose Reduction    \*\* 10E + 5Eq/ml

Interferon still remains the only effective treatment for Hepatitis C infection at present. The optimal duration and dose may still need to be determined. Early trials suggested a better response at higher doses; it has been recommended that patients unresponsive to the standard dose be treated with higher doses.<sup>14</sup> Bellary et al<sup>15</sup> utilized a dose of 5 million units three times a week for 6 months and achieved a 59% reponse rate, but 50% of those with a total reponse had a relapse. Lindsay et al<sup>16</sup> evaluated response rates of 3, 5, or 10 million units given thrice weekly for 12 weeks; those not responding after 12 weeks were then randomized to additional therapy at either the same or higher dose for an additional 12 to 36 weeks. They concluded that the initial response to interferon was not increased by treatment with higher doses of the drug; although marginal, the additional higher doses may still be worth the risk of intolerance to the medication. Vogel et al<sup>17</sup> and Ferenci P et al<sup>18</sup> in Austria reported improved response to doses up to 10 million units but there was varying intolerance to the medication. The treatment may also need to be extended for longer periods as well as an increase in dosage. The toxicity and expense of such regimens must be considered if this is contemplated. Poynard et al<sup>19</sup> extended the interferon treatment randomly for another 12 months after their patients had been treated for 6 months. Those receiving the same dose for an additional 12 months demonstrated a higher percentage with complete ALT and liver histologic reponse.

This early trial reveals only a 4/9 clinical response to Interferon alpha-2b and only 2/9 developed unmeasurable levels of the Hepatitis C virus. Further trials are required since interferon is the only effective treatment at this time.


**Acknowledgements**

We gratefully acknowledge the generosity and support of Schering-Plough Corporation, Kenilworth, NJ for providing recombinant interferon alpha-2b (Intron-A) for patients whose third party payers refused payment and for providing funds for the research HCV-RNA and Genotype testing. We appreciate the HCV PCR analysis provided by Dr Lawrence Lumeng and Dr C.H. Lee, Department of Gastroenterology, Indiana University School of Medicine, Indianapolis, IN. The Nursing Staff, Oncology Unit, St. Francis Medical Center (Jean Nakagawa RN, coordinator) and the Hawaii-Biologi-

cal Response Modifiers Research Staff are acknowledged for their dedication, cooperation and assistance during this interferon treatment protocol with our patients.

**References**

- Hofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant interferon: a preliminary report. *N Eng J Med* 1986;315:1575-1578.
- Davis GL, Bolart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. *N Eng J Med*; 321:1501-1506.
- DiBisceglie AM, Martin PM, Kasiandles C et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. *N Eng J Med* 1989; 321:1506-1510.
- Ching N, Lumeng J, Pang R et al. Long term low dose Interferon alpha 2-b in the treatment of chronic hepatitis B in multi-ethnic patients in Hawaii. *Hawaii Med J.* 1996, 55:201-203.
- Marwick C. Medical News and Perspectives. hepatitis C is focus of NIH panel. *JAMA* 1997; 277:1268-1269.
- Gretch D, Corey L, Wilson J et al. Assessment of hepatitis C virus RNA by quantitative RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. *J Infect Dis* 1994; 169:1219-1225.
- Lau JYN, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. *Lancet* 1993; 341: 1501-1504.
- Martinoi-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy. *Hepatology* 1995; 22: 1050-1056.
- Tsubata A, Kako M, Okamoto H. Factors predictive of response to interferon alpha therapy in hepatitis C virus infection. *Hepatology* 1994; 19:1088-1094.
- Kohara M, Tanaka T, Tsukiyama-Kohana K et al. Hepatitis C virus genotypes 1 and 2 respond to interferon-A with different virologic kinetics. *J Infect Dis* 1995; 172:934-938.
- Simmonds P. Variability of hepatitis C virus. *Hepatology* 1995; 21:570-583.
- Chemello L and Alberli A. Hepatitis C serotype and response to interferon therapy. *N Eng J Med* 1994; 330:143.
- Yamada M, Kakumu SC, Yoshioka K et al. Hepatitis C virus genotypes are not responsible for development of serious liver disease. *Dig Dis Sci* 1994; 39:234-239.
- Schiff ER. Treatment algorithms for hepatitis B and C. *Gut* 1993; 34:s148-149.
- Bellary S, Smith DG, Bankes P et al. High dose interferon a-2b therapy for chronic hepatitis C: an open label study of the response and predictors of response. *Am J Gastroenterol* 1995; 90:259-262.
- Lindsay KL, Davis GL, Schiff ER et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial. Hepatitis intervention therapy group. *Hepatology* 1996; 24:1034-1040.
- Vogel W, Graziadei I, Umlauf F et al. High dose interferon alpha-2b treatment prevents chronicity in acute hepatitis C: A pilot study. *Dig Dis Sci* 1996; 41(12 Suppl):81 S-855.
- Ferenci P, Stauby R, Propst A et al. Dose increase augments response rate to interferon-alpha in chronic hepatitis C. *Dig Dis Sci* 1996; 41(12Suppl): 103S-108S.
- Poynard T, Bedossa P, Chevallier M et al. A comparison of the interferon alfa-2b regimens for the long term treatment of chronic non-a, non-b hepatitis. *N Eng J Med* 1995; 332:1457-1462.



**HAWAII PATHOLOGISTS' LABORATORY**

---

*The Full Service Lab*

*Offering Comprehensive Services in..*

- Clinical Pathology
- Surgical Pathology
- Frozen Section Diagnosis
- Pap Smears
- Special Cytology
- Flow Cytometry
- Fine Needle Aspiration
- Bone Marrow Interpretation
- Specimen Photography
- Image Analysis

1301 Punchbowl Street  
 Honolulu, Hawaii 96813  
 547-4271 Fax 547-4045